Remove 2010 Remove Competition Remove Pharma Remove Relationship management
article thumbnail

Traditional approaches to growth in biopharma are no longer sustainable

pharmaphorum

Through our recent report, Scientific innovations for more sustainable growth , we analysed over 300 M&A deals made by the world’s top 30 biopharma companies between 2010–2021. Collaboration across the industry is needed now more than ever before across this complex ecosystem – not least because it’s becoming a competitive landscape.

article thumbnail

How AI Can Help Medical Science Liaisons Juggle Their Ever-Growing Responsibilities

PM360

1 And, on average , the FDA approved 60% more drugs between 2010-2019 than the yearly average over the previous decade. NSF, “Pharma Pipeline at an All-Time High,” from Informa Pharma R&D Annual Review 2022 (May 2022). The Right Stuff. MSLs do not need another system designed for sales reps. Reference: 1. See resource here.